Last reviewed · How we verify

Ropivacaine 0.25% Injectable Solution

Rothman Institute Orthopaedics · Phase 3 active Small molecule

Ropivacaine is a local anesthetic that works by blocking nerve impulses, preventing pain.

Ropivacaine is a local anesthetic that works by blocking nerve impulses, preventing pain. Used for Postoperative pain management, Regional anesthesia.

At a glance

Generic nameRopivacaine 0.25% Injectable Solution
SponsorRothman Institute Orthopaedics
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

It does this by inhibiting the voltage-gated sodium channels in nerve cells, which are responsible for transmitting pain signals to the brain. This results in a temporary loss of sensation in the affected area.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: